Diffuse large B-cell lymphoma: current strategies and future directions.
Diffuse large B-cell lymphoma (DLBCL) is the most common histology of non-Hodgkin lymphoma, representing 25% to 35% of new cases annually. The incidence of DLBCL has doubled in the past decades, highlighting the need for more effective treatment regimens.
This article reviews the current protocols applicable to this aggressive lymphoma and discusses ongoing research that is focusing on molecular diagnostics, prognostic factors have also been defined for DLBCL.
Patients with DLBCL vary in clinical presentation, prognosis, and response to current therapies. While current therapy in the rituximab era has led to improved outcomes with reduced toxicity, novel treatment approaches for localized, advanced, and relapsed/refractory DLBCL are being pursued in clinical trials. Several studies have shown promise, such as trials involving proteasome inhibitors, lenalidomide, and antibody drug conjugates.
Recent discoveries in the spectrum of care for patients with DLBCL have prompted a renaissance for personalized cancer medicine and molecularly targeted therapy. Potential targets and novel drug combinations are undergoing continued study in the hope of achieving successful and personalized care of this disease.
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA. Jennifer.Cultrera@moffitt.org
SourceCancer control : journal of the Moffitt Cancer Center 19:3 2012 Jul pg 204-13
MeSHAntibodies, Monoclonal, Murine-Derived
Lymphoma, Large B-Cell, Diffuse
Pub Type(s)Journal Article